<DOC>
	<DOCNO>NCT01381484</DOCNO>
	<brief_summary>The purpose study determine whether La Jolie gel effective treatment periorbital wrinkle .</brief_summary>
	<brief_title>Argireline Treatment Periorbital Wrinkles</brief_title>
	<detailed_description>Argireline mechanism action significantly inhibit neurotransmitter release potency similar BoNTA . Inhibition neurotransmitter release due interference hexapeptide formation and/or stability SNARE complex . Notably , peptide exhibit vivo oral toxicity primary irritation high dos . These finding demonstrate Argireline anti-wrinkle peptide emulate action currently use BoNTs . In vivo study , Topical Argireline 10 % applied lateral preorbital area twice daily 30 day . The result demonstrate significant anti-wrinkle activity decrease skin wrinkle 30 % . These finding demonstrate significant anti-wrinkle activity Argireline , agreement vitro cellular activity . Topical Argireline represent bio-safe alternative BoNTs anti-wrinkle therapy .</detailed_description>
	<criteria>healthy woman 3545 year old Presence periorbital wrinkle Pregnancy Nursing Keloids /scar periorbital area pretreatment topical periorbital product within 1 month Botulinum toxin A injection , facial plastic surgery within 1 year Allergic active ingredient include acetyl hexapeptide3 ArgirelineÂ® , sodium hyaluronate , adenosine , arbutin , fucus vesiculosus )</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Periorbital wrinkle</keyword>
	<keyword>Efficacy safety</keyword>
</DOC>